Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

62.85EUR
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
€62.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,028
52-wk High
€63.60
52-wk Low
€45.00

Latest Key Developments (Source: Significant Developments)

DiaSorin FY net profit up 12 pct at EUR 112.6 mln, proposes dividend of EUR 0.80/shr
Wednesday, 8 Mar 2017 08:40am EST 

DiaSorin SpA : Proposes cash dividend of 0.80 euro per share, up 23.1 pct versus 2015 . FY net profit 112.6 million euros ($118.70 million) versus 100.5 million euros a year ago . FY revenue 569.3 million euros versus 499.2 million euros a year ago . 2017 guidance, including unit Focus: revenues up around 11 pct at constant exchange rates (CER), compared with 2016 .2017 guidance, including unit Focus: EBITDA up around 11 pct at CER, compared with 2016.  Full Article

DiaSorin launches test Simplexa C. Difficile Direct in the U.S.
Tuesday, 21 Feb 2017 04:31am EST 

DiaSorin SpA : Launches molecular test Simplexa C. Difficile Direct in the United States .Clostridium difficile Infection (CDI) is a cause of antibiotic-associated diarrhea and colitis.  Full Article

DiaSorin launches test Liaison FGF 23 for chronic kidney disease
Thursday, 26 Jan 2017 05:30am EST 

DiaSorin SpA : Launches test Liaison FGF 23, an automated marker for chronic kidney disease .Liaison FGF 23 to be available worldwide with the exception of the U.S..  Full Article

Diasorin Q3 net profit rises to EUR 28.7 mln
Thursday, 10 Nov 2016 07:15am EST 

Diasorin SpA : Reports Q3 net profit 28.7 million euros ($31.21 million)versus 23.2 million euros a year ago . Q3 revenue 147.0 million euros versus 123.2 million euros a year ago .Confirms previous guidance on revenues and EBITDA for 2016.  Full Article

DiaSorin and Beckman Coulter form partnership to bring hepatitis and HIV tests to U.S.
Tuesday, 30 Aug 2016 04:03am EDT 

DiaSorin SpA : DiaSorin and Beckman Coulter Diagnostics (Beckman Coulter) form strategic partnership to bring Liaison XL hepatitis and HIV products to the United States market . Will work together with Beckman Coulter to submit the products to food and drug administration (FDA) for approval and commercialization in the United States . To offer customers in the United States access to the line of hepatitis and HIV products that can be run on Liaison XL LAS connected to Beckman Coulter's automation solutions . DiaSorin will retain right to commercialize products on Liaison XL stand-alone systems in hospital labs where total laboratory automation (TLA) is not required .Estimates that total available market in the United States for these products, excluding blood bank testing, exceeds $500 million.  Full Article

U.S. HHS awards $2.6 mln to Diasorin group to develop Zika test
Monday, 22 Aug 2016 10:44am EDT 

U.S. Department of Health and Human Services : U.S. HHS Awards $2.6 Million To Diasorin Group To Develop Rapid, High Capacity Zika diagnostic laboratory test . Contract supports development of diagnostic test, manufacturing preparations,clinical trials that could support application for FDA clearance Further company coverage: [DIAS.MI] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

DiaSorin Q2 net profit up 12.0 pct to EUR 29.4 mln
Thursday, 4 Aug 2016 07:57am EDT 

DiaSorin SpA : Q2 net profit 29.4 million euros ($32.73 million), up 12.0 percent year on year . Q2 revenue 141.7 million euros versus 127.5 million euros a year ago . Revises upwards the previous guidance on revenues and EBITDA for 2016, excluding the additional contribution resulting from the recent acquisition of the Focus Diagnostics' business . FY 2016 revenues: sees growth between 6 percent and 7 percent at CER (Constant Exchange Rate) compared with 2015 (previous guidance: growth between 5 percent and 6 percent at CER) .FY 2016 EBITDA: sees growth equal to around 9 percent at CER compared with 2015 (previous guidance: growth equal to around 8 percent at CER).  Full Article

DiaSorin launches test Iam AML1-ETO for screening of acute myeloid leukemia
Thursday, 14 Jul 2016 05:08am EDT 

DiaSorin SpA : Launches Iam AML1-ETO, a test for the molecular screening of acute myeloid leukemia .Test detects the translocation of AML1-ETO, one of the genetic causes of acute myeloid leukemia.  Full Article

Diasorin launches new test for IgG to Helicobacter Pylori detection
Tuesday, 7 Jun 2016 11:41am EDT 

Diasorin Spa :Says launched the new LIAISON test for qualitative detection of IgG to Helicobacter Pylori in human serum.  Full Article

DiaSorin Q1 net profit rises to EUR 24.7 mln
Monday, 9 May 2016 07:42am EDT 

DiaSorin SpA : Q1 revenue 124.5 million euros ($141.69 million) versus 117.6 million euros a year ago . Q1 net profit 24.7 million euros versus 22.6 million euros a year ago . Confirms guidance for 2016 revenues .Raises 2016 EBITDA guidance: growth equal to about 8 percent at CER (Constant Exchange Rates) compared with 2015 (previous guidance: growth between 6 percent and 7 percent at CER).  Full Article

More From Around the Web